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ABSTRACT Bacteriocins, antimicrobial peptides, and
bacteriophagehaveattracted attentionaspotentialsubsti-
tutes for, or as additions to, currently used antimicrobial
compounds. This publication will review research on the
potential application of these alternative antimicrobial
agents topoultry production andprocessing. Bacteriocins
are proteinaceous compounds of bacterial origin that are
lethal to bacteria other than the producing strain. It is
assumed that some of the bacteria in the intestinal tract
produce bacteriocins as a means to achieve a competitive
advantage, and bacteriocin-producing bacteria might be
a desirable part of competitive exclusion preparations.
Puriﬁed or partially puriﬁed bacteriocins could be used
as preservatives or for the reduction or elimination of
certain pathogens. Currently only nisin, produced by cer-
tainstrainsofLactococcuslactissubsp.lactis,hasregulatory
approval for use in certain foods, and its use for poultry
products has been studied extensively. Exploration of the
(Key words: antibiotic alternative, bacteriocin, antimicrobial peptide, bacteriophage)
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INTRODUCTION
Antibiotics have been utilized in animal research al-
most from the time of their discovery and quickly found
widespread use in the farm environment as therapeutic
agents and as growth promotants. By the early 1950s, a
substantial number of publications concerning the
growth-promoting effect of antibiotics on poultry had
appeared (Branion et al., 1953). The U.S. Food and Drug
Administration ﬁrst approved certain antibiotics for use
in animal feed in 1951 and now maintains a list of cur-
rently approved products (Center for Veterinary Medi-
cine, 2002). Although exact ﬁgures on current use of anti-
biotics in the farm environment are apparently not avail-
able, estimates as high as 10.5 million pounds annually
in the United States for the poultry production have been
circulated (Mellon et al., 2001).
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application of antimicrobial peptides from sources other
than bacteria to poultry has not yet commenced to a
signiﬁcant extent. Evidence for the ability of chickens to
produce such antimicrobial peptides has been provided,
and it is likely that these peptides play an important role
in the defense against various pathogens. Bacteriophages
have received renewed attention as possible agents
against infecting bacteria. Evidence from several trials
indicatesthatphagetherapycanbeeffectiveundercertain
circumstances. Numerous obstacles for the use of phage
as antimicrobials for poultry or poultry products remain.
Chieﬂy among them are the narrow host range of many
phages, the issue of phage resistance, and the possibility
ofphage-mediatedtransferofgeneticmaterialtobacterial
hosts. Regulatory issues and the high cost of producing
such alternative antimicrobial agents are also factors that
might prevent application of these agents in the near
future.
The efﬁcacy and cost-effectiveness of many of these
compounds are at the root of their popularity, but loom-
ing or already imposed restrictions or prohibitions on
the use antibiotics as growth promotants have drawn
attention to possible alternatives (Bedford, 2000; Wierup,
2000; Doyle, 2001). The use of antibiotics for the treatment
of animals suffering from parasitic or bacterial infections
is rarely questioned as long as the diseases have been
diagnosed correctly and the dosage and duration of treat-
ment follow prescriptive measures. But even for these
therapeutic applications, it would be desirable to ﬁnd
compounds with fewer ties to human antimicrobial
therapies.
Over the years, and especially more recently, a number
of strategies for improvements in animal health, produc-
tivity, and microbial food safety that did not involve anti-
biotics have been explored. Probiotics and competitive
exclusion preparations have been studied for application
in poultry production, and some are already in use
(Nurmi and Rantala, 1973; Bailey, 1987; Stavric, 1987; Sta-
vric and D’Aoust, 1993; Corrier et al., 1995; DeLoach,
1998).
Theadditionofenzymeshasbeenfoundtobebeneﬁcial
depending on the feed ingredients used (Choct, 2001;
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Maenz,2001).Orallyadministeredchickeneggantibodies
have shown promise for treatment of intestinal infections
in pigs and calves (Yokoyama et al., 1992; Zuniga et al.,
1997; Yokoyama et al., 1998), and cytokines have been
shown to act as growth promoters and immuno-en-
hancers for broiler chickens (Lowenthal et al., 1999). Nu-
merous nutritional additives are either already in use
or have been proposed as means to reduce or eliminate
pathogens or as a means to improve growth and feed
conversion. In addition, agents such as bacteriocins, anti-
microbial peptides, and bacteriophages have been stud-
ied or proposed as potential animal therapeutics. This
review will discuss some of the challenges faced by these
agents for antimicrobial therapy and their potential for
use as growth promotants.
BACTERIOCINS
Bacteriocins are proteinaceous compounds lethal to
bacteria other than the producing strain. As a group,
bacteriocins are heterogeneous, and they are classiﬁed
largely based on their molecular weight differences
(Klaenhammer, 1993). Some bacteriocins are peptides
consisting of only 19 to 37 amino acids, whereas others
are large peptides with molecular weights of up to 90,000.
Some small bacteriocins contain unusual amino acids
originating from modiﬁcations of conventional amino
acids after translation. The activity spectrum of bacterio-
cins can be narrow and conﬁned to inhibition of closely
related species, or it can be relatively broad and include
many different bacterial species.
Incontrasttothecurrentlyusedantibiotics,bacteriocins
are often considered more natural because they are
thought to have been present in many of the foods eaten
since ancient times (Cleveland et al., 2001). The bacterio-
cin nisin actually has GRAS (generally recognized as safe)
status (21 CFR 184.1538). Nisin and other bacteriocins
produced by lactic acid bacteria have received a great
deal of attention because they are produced by bacteria
largely considered beneﬁcial to human health and to
food production.
In most cases, bacteriocin production and activity has
been demonstrated only in the laboratory. Evidence for
a role played by bacteriocins in natural systems such as
the intestinal tract is largely circumstantial. The observa-
tion that many intestinal bacteria such as Fusobacterium
mortiferum isolatedfrom chicken ceca(Portrait etal., 2000)
are able to synthesize bacteriocins in vitro supports the
notion that bacteriocins might be useful for survival in
the intestinal tract. Some data from experiments with
bacteriocin-producing bacteria also suggest an inﬂuence
of bacteriocins on the ecology of the intestinal microbiota.
For example, an avian Escherichia coli strain genetically
engineered to produce the bacteriocin microcin 24 low-
ered intestinal Salmonella typhimurium counts in chickens
when administered continuously in the water supply
(Wooley et al., 1999). Similarly, the bacteriocin-producing
Enterococcus faecium strain J96 isolated from the crop of
a chicken exhibited some protective effect on chicks in-
fected with S. pullorum (Audisio et al., 2000).
The administration of bacteriocin-producing bacteria
rather than the bacteriocins themselves might be a more
cost-effective approach, but signiﬁcant progress in devel-
oping suitable producer strains will have to be made
before such an approach will be feasible. Few studies
have addressed the fate of bacteriocins in the intestinal
tract, but some data suggest that some of the low molecu-
lar weight bacteriocins can survive at least some of the
intestinal environments and possibly could be adminis-
teredwithfeed.Forexample,Gaenzleetal.(1999)demon-
strated that Lactobacillus curvatus, a producer of the bacte-
riocin curvacin, contributed to the inactivation of E. coli
and strongly inhibited Listeria innocua in the gastric com-
partment of a dynamic model of the stomach and small
intestine. During transit through the model system, the
bacteriocin was not degraded in the gastric compartment
and was degraded in the ileal compartment over approxi-
mately 180 min. Jalc and Laukove (2002) introduced nisin
into an artiﬁcial rumen system and detected some
changes in fermentation parameters such as an increase
in hemicellulose degradation and acetate and propionate
production. It is likely that these changes resulted from
changes in microbial activities, but it is not known which
bacteria were affected.
Applicationsofabacteriocininpoultryprocessinghave
been exploredby Mahadeo andTatini (1994)who demon-
strated that nisin reduced the number of Listeria added
to scald water from a poultry processing plant by two
ordersofmagnitude,followedbyfurtherreductionsupon
refrigeration. Listeria cells attached to poultry skin were
more difﬁcult to inactivate with nisin, and only about
one log10 reduction was observed from an initial count of
approximately 106 cfu. Although gram-negative bacteria
such as Salmonella are considerably less sensitive to nisin
than are many of the gram-positive bacteria, additions of
chelating agents such as EDTA and detergents such as
Tween 80 have been used to enhance the activity of nisin
against gram-negative bacteria. Simultaneous delivery of
nisin, EDTA, and Tween 80 under acidic conditions via
an alginate or agarose-based gel onto the skin of chicken
parts experimentally contaminated with S. typhimurium
reduced counts of this pathogen by up to 3 log10 after 72
ha t4 °C (Natrajan and Sheldon, 2000a). The shelf life of
refrigerated broiler drumsticks was extended by 0.6 to
2.2dbydippinginanisin-containingsolutionandstorage
under nisin-treated PVC overwrap and on nisin-treated
tray pads (Natrajan and Sheldon, 2000b).
Aswithany antimicrobialcompound,theissue ofresis-
tance also has to be considered for bacteriocins. Although
the mechanism of action is not known for all bacteriocins,
most of the low molecular weight bacteriocins appear
to interact with the bacterial membrane. Resistance is
therefore usually the result of changes in the membrane
of bacteria targeted by a bacteriocin (Ming and Daeschel,
1993; Mazzotta et al., 1997; Crandall and Montville, 1998),
but inactivation by degradation has been observed for
nisin (Jarvis, 1967). Until recently, development of resis-
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 JOERGER 642
tanceto bacteriocinswasnot consideredas affectingresis-
tance to currently used antibiotics; however, Carlson et
al. (2001) demonstrated that exposure of Salmonella to the
bacteriocin microcin-24 can result in microcin-resistant
cellsexhibitingresistancetomultiplecommonantibiotics.
It remains to be seen if this observation is unique or if
certain other bacteriocins can produce similar effects. Of
concern is also a report by Mantovani and Russell (2001)
that nisin-resistant mutants of Streptococcus bovis exhib-
ited a 1,000-fold higher resistance to ampicillin than the
original nisin-sensitive isolates.
For uses involving puriﬁed bacteriocins, cost of the
compounds can become a signiﬁcant barrier. Production
of all but the smallest bacteriocins is currently only imag-
inable by culture of natural or genetically engineered pro-
ducer organisms. Investments in research and develop-
ment can be expected to be high, and the size of the
market is difﬁcult to predict, but the fact that nisin has
found commercial uses indicates that economic aspects
are not insurmountable barriers to bacteriocin appli-
cations.
ANTIMICROBIAL PEPTIDES
The production of small antimicrobial peptides is not
conﬁned to bacteria, but appears to occur in all organisms
studied so far. Such natural peptides as well as artiﬁcial
peptides derived by combinatory chemistry or rational
designhaveattractedgreatattentioninrecentyears(Han-
cock, 1997; Hancock and Lehrer, 1998). Numerous publi-
cations such as the ones by Gennaro and Zanetti (2000)
and van ’t Hof et al. (2001) have reviewed general and
speciﬁc aspects of antimicrobial peptides, their biochem-
istry, and potential uses, but the scope of this paper does
notallowadetaileddiscussionofallthetopics.Ingeneral,
antimicrobialpeptidesaresmallmoleculeswithamolecu-
lar mass of 1 to 5 kDa. Their structure usually contains
elements that facilitate the interaction with negatively
charged membranes, and their mode of action involves
the cell membranes of target organisms (Hancock and
Rozek, 2002). In this respect, these peptides resemble
some of the small bacteriocins such as nisin, and the
development of resistance to the eucaryotic peptides
might therefore also require changes to the membrane.
Development of strains resistant to antimicrobial pep-
tides from previously sensitive strains has been viewed
as difﬁcult if not impossible (Hancock, 1997; van ’t Hof
et al., 2001), but studies have shown that certain genes
can confer increased resistance to antimicrobial peptides.
An example is a gene, rcp, present in Legionella pneumoph-
ila (Robey et al., 2001). Some resistance determinants
against certain antimicrobial peptides have also been ob-
servedinStaphylococcus(reviewedbyPeschelandCollins,
2001).Whether ornot theseand otherasyet undiscovered
determinants can be transferred between bacteria is cur-
rently not known.
The ubiquitous nature of antimicrobial peptides sug-
gests that their role in nature has been long standing and
must have contributed to an organism’s ﬁtness. It is not
known if poultry currently used for food production has
maintained ancestral levels of antimicrobial peptides or
whether intense breeding efforts have led to their decline.
Perhaps with increased knowledge of the genome and of
gene expression patterns of chickens, this question can
be addressed, and, ultimately, selection or perhaps even
genetic engineering can restore or increase the activity of
poultry antimicrobial peptides. The full range of chicken
antimicrobial peptides and their contribution to a chick-
en’s overall health and maintenance of favorable intesti-
nal microbiota are currently not known, but research has
already uncovered some of the peptides and some of the
gene sequences that potentially code for them. Harwig
et al. (1994) puriﬁed three antimicrobial peptides (galli-
nacins) from chicken leukocytes and examined their anti-
microbial cativity in vitro. The peptides inhibited L. mono-
cytogenes and E. coli, and two of the three peptides were
also effective against the yeast Candida albicans. Three
peptides isolated from turkey heterophil granules were
tested against Staphylococcus aureus and E. coli. The three
peptides killed S. aureus, and two of the three also killed
E. coli (Evans et al., 1994). In a subsequent study with
two chicken and twoturkey peptides, antimicrobial activ-
ity was demonstrated against Candida albicans, S. enteriti-
dis, and Campylobacter jejuni. Pasteurella multocida was not
affected (Evans et al., 1995). One of the turkey peptides
did not reduce survival of Bordetella avium, E. coli, and S.
typhimurim, and none of the peptides neutralized infec-
tious bronchitis virus. mRNA-derived sequences for four
of the avian peptides were characterized subsequently
(Brockus et al., 1998). A chicken epithelial β-defensin was
shown to be inducible by experimental infection with
Haemophilus paragallinarum (Zhao et al., 2001). This obser-
vation suggests a role for these types of peptides in ﬁght-
ing bacterial disease.
Sequences that potentially encode antimicrobial pep-
tides have also been detected in a cDNA library from
chicken macrophages (Keeler, unpublished). Among the
cDNAwasa sequencethatcouldencodea peptiderelated
to cathelicidins. Based on the predicted amino acid se-
quence, the peptide was synthesized chemically and
tested against the three pathogenic bacteria, E. coli
O157:H7, S. enteritidis, and L. monocytogenes. When added
to approximately 104 cfu/mL of the pathogens in trypti-
case soy broth, visible growth after 16 h of incubation at
37°C was not detected when the peptide was added in
concentrations equal to or higher than 12.5, 25, and 12.5
µg/mL for E. coli O157:H7, S. enteritidis, and L. monocyto-
genes, respectively (Joerger, unpublished data).
As with bacteriocins, the proteinaceous nature of anti-
microbial peptides makes them vulnerable to proteolytic
enzymes. This instability is probably of little concern for
peptides produced in the immune system or epithelium
where bacterial targets are in close range. Some of the
peptides such as defensins or bactenecin exhibit toxic
effects (Rademacher et al., 1993; Kagan et al., 1994), and
proteolysis might limit this effect by reducing the range
and concentration of the peptides. In contrast, any inter-
vention that involves injection or ingestion of such pep-
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tides will have to deal with the potential for proteolysis
and toxicity. Perhaps, the peptides have to be modiﬁed
chemically to make them more resistant to proteolysis in
animals, or their administration might have to include
encapsulation methods that protect the peptides from
immediate attack. Both strategies would add to the costs
of antimicrobial peptide treatment.
Currently, chemical synthesis appears too costly for
large-scaleproductionofpeptides,andbiologicalproduc-
tionwithmicroorganisms,tissuecultures,orintransgenic
animals will probably have to be attempted. Transgenic
plants could be used for production of peptides (van t’
Hof et al., 2001), and perhaps for some applications, the
peptide-containing plant material could be added to ani-
mal feed. The prospects for such an approach are cur-
rently rather uncertain because important economic and
ecological issues need to be resolved; however, in antici-
pation of the development of plants expressing traits of
medicinal interest, the FDA has initiated the process of
developing guidelines (Food and Drug Administration,
2002).
Extensive research will be required to identify peptides
that inﬂuence intestinal microbiota in the same way as
currently used antibiotics. Perhaps a more likely use for
antimicrobialpeptidesinthenot-too-distantfuturewould
be as inhibitors of microbial growth on surfaces and in
biological material such as vaccines. Such an application
would require smaller amounts of the peptides than feed
applications, and enzymatic degradation would also be
of less concern.
BACTERIOPHAGES
Bacteriophages are viruses that infect and multiply in
bacteria. For many bacteriophages, release into the envi-
ronment after replication is accompanied by lysis of the
host bacterium. This event is easily observed in test tubes
andonagarplates(plaqueformation),anditsexploitation
forkillinginfectiousbacteriawassuggestedalmostimme-
diately upon discovery. The enormous suffering caused
by bacteria directed the ﬁrst therapeutic efforts toward
treatment of infections in humans,but the initial euphoria
about phage as therapeutic agents dissipated with the
onset of the antibiotic era. In addition, many earlier trials
with phage did not produce desired outcomes. To a lim-
ited extent, phage therapy continued to be practiced in
some Eastern European countries, but was reexamined in
WesternEuropeandtheUnitedStatesonlyafterproblems
with antibiotic-resistant bacteria began to surface. Since
then, a number of papers reviewing historical aspects of
phage therapy and applying mathematical modeling to
explain observed phenomena have appeared (Levin and
Bull, 1996; Alisky et al., 1998; Pirisi, 2000; Chanishvili et
al., 2001; Payne and Jansen, 2001; Sulakvelidze and Mor-
ris, 2001; Summers, 2001, Kasman et al., 2002). A consen-
sus appears to have emerged on the feasibility of phage
therapy under the right conditions, but it is also clear
that signiﬁcant research efforts will be necessary before
phage therapy can be implemented.
Not all phages would be suitable for phage therapy.
Detailed studies of potentially useful phages with respect
to their interaction with target bacteria and their genetic
content will be required. Some phages produce progeny
withoutdestroyingtheirbacterialhost,othershavemeans
to temporarily integrate their genome into that of the
bacterium where it is replicated along with the bacterial
genome and potentially introduces new traits or modiﬁes
the expression of host traits. While part of the bacterial
genome, the phage DNA sequences can participate in
recombination events, leading to modiﬁcations of the
phage genomes. There are now numerous accounts of
phage encoding virulence genes or of phage integrated
into bacterial genomes that inﬂuence expression of bacte-
rial genes, among them toxin- or antibiotic-resistance
genes (Schicklmaier and Schmieger, 1995; Alisky et al.,
1998; Figueroa-Bossi and Bossi, 1999; Schmieger and
Schicklmaier, 1999; Mirold et al., 2001). Gene ﬂow among
phages and hosts appears to be common, resulting in
phage genomes that are mosaics of sequences of different
origins. (Hendrix et al., 1999; Juhala et al., 2000) Excision
and replication of the integrated phage DNA for produc-
tion of new phage particles can sometimes lead to inclu-
sionofbacterialsequencesthatcansubsequentlybetrans-
ferred into new host cells. Therefore, phages that infect
their hosts, initiate replication and production of progeny
immediately, and cause cell lysis are preferred for phage
therapy because they lead to relatively fast destruction
of many of the bacterial targets, and there are fewer op-
portunities for interactions with the bacterial genome.
One feature that makes bacteriophage so attractive is
their highly discriminatory nature. Most of the known
bacteriophages are specialists that interact only with a
speciﬁc set of bacteria that express speciﬁc binding sites;
bacteria without these receptors are not affected. This
narrow host range is alsoa signiﬁcant challenge for phage
therapy. For example, there is no known phage that is
lytic for all Salmonella serovars. More likely, a particular
Salmonella phage will only lyse a small part of the spec-
trum of Salmonella serovars and even will not be lytic for
all members of one particular serovar. This observation
was also made in a study on the use of phages to combat
infections of chicks with S. enteritidis (Sklar and Joerger,
2001). This degree of host speciﬁcity necessitates use of
phage mixtures for prophylaxis of bacterial infections in
most instances.
Chighladze et al. (2001) isolated Salmonella phages and
combined them into a cocktail that was lytic to 232 of
245 Salmonella isolates representing 21 sero and 78 PFGE
types. The number of different Salmonella phages in the
cocktail was not revealed. Application of this cocktail to
artiﬁcially contaminated surfaces reduced Salmonella to
undetectable levels after 48 h, and three log10 units of
decrease in Salmonella counts were reported for phage-
treated eggs. Reductions in Salmonella counts from artiﬁ-
cially contaminated carcasses were also observed.
Use of several different phages for combating even a
single bacterial strain has been found necessary in several
studies. Kudva et al. (1999) employed a mixture of phage
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against a strain of E. coli O157:H7, as did Schnabel et
al. (1999) in a study with the plant pathogen Erwinia
amylovora. Sklar and Joerger (2001) also used combina-
tions of S. enteritidis phages in their study with young
chickens because individual phage did not result in a
decrease in cecal counts of S. enteritidis at 14 d of age.
Almost certainly, phage-based modiﬁcation of the intesti-
nal microbiota for growth promotion would also require
use of several phages in one preparation.
Most of the experimental studies on phage therapy
have used model systems that included potentially lethal
bacterial infections (Soothill, 1992; Merril et al., 1996; Bis-
was et al., 2002). In most cases, successful treatment out-
comes (survival) were reported. Recently, Huff et al.
(2002) described successful application of phage in pre-
vention of E. coli infections in broiler chickens. The results
from experiments with models not involving bacteremia
were not always as encouraging. Smith et al. (1987) re-
ported that phage were able to cure E. coli-induced diar-
rheaincalves.Reynaudetal.(1992)wasunabletodemon-
strate this in a rabbit model. Berchieri et al. (1991) ob-
served reduced mortality in S. typhimurium-infected
chicks and some reduction of counts for this bacterium
in the intestinal tract and the liver. Sklar and Joerger
(2001) observed counts of S. enteritidis that were lower
by 0.3 to 1.3 orders of magnitude in the ceca of phage-
treated chickens than in ceca from untreated birds.
Therapy or prophylaxis against intestinal bacteria
might be more difﬁcult for several reasons. In contrast to
phage therapy for bacteremia, intestinal phage therapy
might have little or no support from the immune system.
Anytargetbacteriathatescapephageattackorthatharbor
resistance mechanisms will be able to multiply and per-
haps establish population levels comparable to those
prior to phage administration. Although earlier concerns
based on the studies by Wiggins and Alexander (1985)
regarding the minimum number of bacteria required for
phage propagation have been rejected recently (Payne
and Jansen, 2001), other concerns are still valid.
In a relatively ﬂuid environment such as broth or even
blood, mixing and diffusion are relatively unimpeded;
theviscosityofintestinalcontentontheotherhandwould
appear to reduce the chance of bacteria-phage collisions
and higher phage concentrations relative to the bacteria
might be required for effective treatment. In addition, the
large numbers of bacteria found in certain parts of the
intestinal tract might not only be mechanical barriers to
diffusion of phages, but some of the bacteria might also
exhibit nonspeciﬁc phage binding.
It has also been proposed that differences between the
physiologyofbacteriagrownunderlaboratoryconditions
and of bacteria inhabiting host environments could ac-
count for some of the failures of phage therapy attempts.
Perhaps a fraction or even most of the bacteria inside the
host do no longer express the phage receptors prevalent
in laboratory culture. The bacterial physiology could also
be such that phage replication is slower or perhaps com-
pletelyinhibited.Phagesthatselectivelybindtoandrepli-
cate in bacteria of different physiological states have been
recognized. For example, Lui et al. (2002) described
phages that replicate in either free-living Bordetella bron-
chiseptica or in the host-associate form of the bacterium.
During phage treatment, phages are exposed to a num-
ber of factors that might limit their activity. Phages circu-
lating in the blood stream are potentially subject to attack
by antibodies, or they can be removed from circulation
bythe reticuloendothelialsystem. Selectionof phagevari-
ants not as susceptible to removal from circulation in the
body is feasible (Merril et al. 1996). Potentially adverse
factors encountered in the intestinal tract are pH varia-
tions and the presence of enzymes and other digestive
compounds such as bile. Phages have been observed in
several intestinal systems and have been studied more
extensively in the rumen where a dynamic phage popula-
tion of up to 1.6 × 1010 phage particles per milliliter of
rumenﬂuidwasdetectable(KlieveandSwain1993).Most
of the phages that target bacteria inhabiting intestinal
sites are probably well adapted to the intestinal environ-
ment; for example, they remain viable in the fermentative
environment of the cecum of chickens (Berchieri et al.,
1991; Sklar and Joerger, 2001).
Whether or not phage activity is the same in all com-
partments of the intestinal system is not known. Sklar
and Joerger (2001) observed that chickens experimentally
infected with S. enteritidis and treated orally with phages
were sometimes negative for Salmonella in cloacal swab
tests even though they harbored signiﬁcant numbers of
S. enteritidis in their ceca. Infected chickens not exposed
to the phages tested positive for Salmonella in cloacal
swabs and in cecal samples. These observations might be
the result of the testing methodology (swabbing vs. plat-
ing of diluted samples), but it is also possible that phage
activity was more pronounced in the lower regions of the
chickens, thus reducing shedding. Leverentz et al. (2001)
suggested that pH can have an effect on phage activity
becauseaphage preparationwasabletoreduce S.enteriti-
dis counts on experimentally contaminated melons but
not on apple slices (pH 4.2).
Bacteriophages are generally very stable entities and
survive storage relatively well, even when absorbed to
solid particles. For example, a titer of 109 plaque-forming
units (cfu) of a Salmonella phage mixed with chicken feed
pellets decreased by only approximately two orders of
magnitude over 14 d at 37°C (Sklar and Joerger, 2001).
In most respects, the same technical and ﬁnancial chal-
lenges faced by most other large-scale operations involv-
ing microorganisms are also present for the production of
phages. One signiﬁcant difference between most current
operations and phage production could be safety con-
cerns regarding the bacterial host. If it were necessary
to produce therapeutic phage in their pathogenic hosts,
relatively costly safety measures to protect plant workers
and the surrounding community would have to be imple-
mented. Inherent with propagation of phage on a patho-
genic host is also the risk of production of some phage
that carry host DNA involved in pathogenicity that could
conceivably be transferred to other bacteria. Although
thelikelihoodofsuchaneventmightbesmall,itwouldbe
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preferable to produce phage in hosts that are not virulent.
Perhaps non-virulent, genetically well-characterized
hosts can be found for the propagation of phage, but
development of such bacteria will also add to the cost of
development of phage preparations.
In vitro assembly of phage particles that contain DNA
coding for bactericidal proteins, but not for any function
allowing phage replication, could eliminate problems
with the release of large numbers of phage capable of
infection of new hosts. On the other hand, such phages
would also no longer be able to multiply thus potentially
reducing the therapeutic effect.
Despite a paucity of experimental data, a certain
amount of optimism has been expressed that medical
applications will be pursued in the not too distant future
(Pirisi, 2000). Phage therapy might become an addition
to the collection of antibacterial tools and will be used
perhaps primarily when other, cheaper means such as
conventional antibiotics fail. Presumably, such occasional
application of phage will cause fewer ecological concerns
than application of phage to entire ﬂocks or herds of
animals. Theescape ofphage fromsuch facilitiesis proba-
blyinevitableandcouldbeperceivedasanenvironmental
risk. The public might consider such a risk as too high,
but, as observed with the issue of genetic engineering,
might display a more accepting attitude toward medi-
cal applications.
For some applications, it might not be necessary to
apply active phage, but simply to administer the en-
zyme(s) used by a particular phage to lyse their bacterial
host. Loefﬂer at al. (2001) demonstrated the feasibility of
this approach on mice infected with pneumococci. This
approachmightbemostsuitableforthetreatmentoftopic
infections or infections of mucous membranes.
Arguably, bacteriophages are the most promising
agents that could complement and sometimes replace
current antibiotics, but their use on the farm or for food
safety applications is uncertain. Small antimicrobial pep-
tides whether of bacterial or eucaryotic origin or created
artiﬁcially in the test tube will more likely become avail-
able for animal applications, but substantial research ef-
forts will still be necessaryto realize that possibility. Their
use for treatment of diseases will be probably at the fore-
front; their development as growth promotants will be
more difﬁcult, especially since the bacterial targets for
the growth promotants are not fully known.
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